Back to results
US 6,787,566 B2Granted
Breakers of advanced glycation endproducts
AssigneeCity of Hope
InventorSamuel Rahbar
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeCity of Hope
InventorSamuel Rahbar
Estimating the term…
Advanced glycation endproducts (AGEs) have been implicated in the pathogenesis of a variety of debilitating diseases such as diabetes, atherosclerosis, Alzheimer's and rheumatoid arthritis, as well as in the normal aging process. Seven compounds are here reported to be active in breaking AGE-protein cross-links. These compounds are 1,4-benzene-bis[4-methyleneaminophenoxyisobutyric acid] (LR102); 4-[(3,5-dichlorophenylureidophenoxyisobutyryl]-4-aminobenzoic acid (LR99); L-bis-[4-(4-chlorobenzamidophenoxyisobutyryl)cystine] (LR20); 4-(3,5-dichlorophenylureido)phenoxyisobutyryl-1-amidocyclohexane-1-carboxylic acid (LR23); methylene bis [4,4′-(2-chlorophenylureidophenoxyisobutyric acid)] (LR90); 5-aminosalicylic acid (5-ASA); and metformin. These compounds may be used to reverse the debilitating effects of those diseases in which AGEs are formed.
A method for cleaving glycation endproducts or cross-linked proteins in an organism, wherein said method comprises administering an effective amount of a compound or a pharmaceutically acceptable salt of said compound to said organism wherein said compound is selected from the group consisting of:
A method of treating deleterious effects of aging in an organism, wherein said effects are formation of glycation endproducts or protein cross-linking, wherein said method comprises administering an effective amount of a compound or a pharmaceutically acceptable salt of said compound to said organism wherein said compound is selected from the group consisting of:
A method of treating complications resulting from diabetes, wherein said complications result from formation of glycation endproducts or protein cross-linking, wherein said method comprises administering an effective amount of a compound or a pharmaceutically acceptable salt of said compound to said organism wherein said compound is selected from the group consisting of:
A method of treating a patient having rheumatoid arthritis, Alzbeimer's disease, uremia, neurotoxicity, or atherosclerosis by cleaving advanced glycation endproducts or cross-linked proteins, wherein said method comprises administering an effective amount of a compound or a pharmaceutically acceptable salt of said compound to said patient wherein said compound is selected from the group consisting of:
Dependencies are inferred from the claim text.